Valneva SE (NASDAQ:VALN) Short Interest Down 20.6% in December

Posted by Jeff Wilder on Dec 29th, 2024

Valneva SE (NASDAQ:VALN – Get Free Report) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 24,300 shares, a decrease of 20.6% from the November 30th total of 30,600 shares. Based on an average daily trading volume, of 30,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their target price on shares of Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, October 11th.

Get Our Latest Stock Report on VALN

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC raised its stake in Valneva SE (NASDAQ:VALN – Free Report) by 33.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Price Performance

Shares of Valneva stock traded up $0.13 during trading on Friday, hitting $4.33. The stock had a trading volume of 108,759 shares, compared to its average volume of 16,618. The firm has a market cap of $351.86 million, a price-to-earnings ratio of -33.31 and a beta of 1.98. Valneva has a 12 month low of $3.62 and a 12 month high of $10.76. The business’s 50-day moving average is $4.70 and its 200 day moving average is $6.16. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

About Valneva

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.